. Author manuscript; available in PMC: 2020 Mar 1.

Published in final edited form as: Clin Pharmacol Ther. 2018 Oct 18;105(3):703–709. doi: 10.1002/cpt.1233

Table 3:

Association between concurrent prescription of tizanidine and a CYP1A2 inhibitor and hypotension (SBP<90 mm Hg)

	Tizanidine (n=1,626)	Cyclobenzaprine (n=5,012)	p-value
Windows with event (SBP<90 mm Hg)	159	377
Rate of Event (%)	9.78	7.52	0.005
Odds Ratio (95% CI)	1.33 (1.10, 1.62)	Reference	0.004
Odds Ratio – adjusted for age, race, and sex	1.33 (1.09, 1.63)	Reference	0.005
Adjusted for logarithmically transformed PS^*	1.26 (1.03, 1.54)	Reference	0.025

PS included the following variables: age, use of ciprofloxacin vs fluvoxamine, race, sex, Charlson score, current use of ARBs, ACE inhibitors, beta-blockers, calcium channel blockers, diuretics, alpha-agonist agents, and other antihypertensive agents.